{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:25:09Z","timestamp":1790601909435,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since the introduction of artemisinin-based combination therapy (ACT) in Ghana in 2005 there has been a surveillance system by the National Malaria Control Programme (NMCP) and the University of Ghana Noguchi Memorial Institute for Medical Research (UG-NMIMR) to monitor the therapeutic efficacy of ACTs for the treatment of uncomplicated malaria in the country. We report trends and determinants of failure following treatment of Ghanaian children with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Per protocol analyses as well as cumulative incidence of day 28 treatment failure from Kaplan Meier survival analyses were used to describe trends of failure over the surveillance period of 2005\u20132018. Univariable and multivariable cox regression analyses were used to assess the determinants of treatment failure over the period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Day 28 PCR-corrected failure, following treatment with ASAQ, significantly increased from 0.0% in 2005 to 2.0% (95% CI: 1.1\u20133.6) in 2015 (p\u2009=\u20090.013) but significantly decreased to 0.4% (95% CI: 0.1\u20131.6) in 2018 (p\u2009=\u20090.039). Failure, following treatment with AL, decreased from 4.5% (95% CI: 2.0\u20139.4) in 2010 to 2.7% (95% CI: 1.4\u20135.1) in 2018, though not statistically significant (p\u2009=\u20090.426). Risk of treatment failure, from multivariable cox regression analyses, was significantly lower among children receiving ASAQ compared with those receiving AL (HR\u2009=\u20090.24; 95% CI: 0.11\u20130.53; p\u2009&lt;\u20090.001); lower among children with no parasitaemia on day 3 compared with those with parasitaemia on day 3 (HR\u2009=\u20090.02; 95% CI: 0.01\u20130.13; p\u2009&lt;\u20090.001); and higher among children who received ASAQ and had axillary temperature\u2009\u2265\u200937.5\u00a0\u00b0C on day 1 compared with those with axillary temperature\u2009&lt;\u200937.5\u00a0\u00b0C (HR\u2009=\u20093.96; 95% CI: 1.61\u20139.75; p\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment failures for both ASAQ and AL have remained less than 5% (below WHO\u2019s threshold of 10%) in Ghana since 2005. Predictors of treatment failure that need to be considered in the management of uncomplicated malaria in the country should include type of ACT, day 3 parasitaemia, and day 1 axillary temperature of patients being treated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06961-4","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:06:46Z","timestamp":1639562806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005\u20132018"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1840-6979","authenticated-orcid":false,"given":"Benjamin","family":"Abuaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-1793","authenticated-orcid":false,"given":"Nancy Odurowah","family":"Duah-Quashie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-0324","authenticated-orcid":false,"given":"Neils","family":"Quashie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akosua","family":"Gyasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-0511","authenticated-orcid":false,"given":"Patricia Opoku","family":"Afriyie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Owusu-Antwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-1249","authenticated-orcid":false,"given":"Anita","family":"Ghansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah Laurencia","family":"Malm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Bart-Plange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-6516","authenticated-orcid":false,"given":"Kwadwo Ansah","family":"Koram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"6961_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-3305-3-5","volume":"3","author":"FEG Cox","year":"2010","unstructured":"Cox FEG. History of the discovery of the malaria parasites and their vectors. Parasit Vectors. 2010;3:5.","journal-title":"Parasit Vectors"},{"key":"6961_CR2","volume-title":"World malaria report 2005","author":"World Health Organization and UNICEF","year":"2005","unstructured":"World Health Organization and UNICEF. World malaria report 2005. Geneva: World Health Organization; 2005."},{"key":"6961_CR3","doi-asserted-by":"publisher","DOI":"10.30875\/7e6f8c91-en","volume-title":"World malaria report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. World malaria report 2019. Geneva: World Health Organization; 2019."},{"key":"6961_CR4","volume-title":"Ghana Malaria Indicator Survey 2019","author":"Ghana Statistical Service (GSS) and ICF","year":"2020","unstructured":"Ghana Statistical Service (GSS) and ICF. Ghana Malaria Indicator Survey 2019. Accra: GSS and ICF; 2020."},{"key":"6961_CR5","unstructured":"World Health Organization. Global Technical Strategy for Malaria 2016\u20132030. https:\/\/www.who.int\/docs\/default-source\/documents\/global-technical-strategy-for-malaria-2016-2030.pdf? Accessed 4 Nov 2020."},{"key":"6961_CR6","unstructured":"World Health Organization. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies, Geneva, 19 April 2006. https:\/\/www.who.int\/malaria\/publications\/atoz\/meeting_briefing19april.pdf. Accessed 2 Jul 2021."},{"issue":"8","key":"6961_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1586\/eri.09.68","volume":"7","author":"L Cui","year":"2009","unstructured":"Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009;7(8):999\u20131013.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"6961_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1128\/CMR.17.1.235-254.2004","volume":"17","author":"AO Talisuna","year":"2004","unstructured":"Talisuna AO, Bloland P, D\u2019Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004;17(1):235\u201354.","journal-title":"Clin Microbiol Rev"},{"key":"6961_CR9","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"6961_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.actatropica.2005.06.018","volume":"95","author":"KA Koram","year":"2005","unstructured":"Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95:194\u2013203.","journal-title":"Acta Trop"},{"key":"6961_CR11","volume-title":"Guidelines for case management of malaria in Ghana","author":"Ministry of Health","year":"2009","unstructured":"Ministry of Health. Guidelines for case management of malaria in Ghana. Accra: Ministry of Health; 2009."},{"key":"6961_CR12","volume-title":"Guidelines for case management of malaria in Ghana","author":"Ministry of Health","year":"2020","unstructured":"Ministry of Health. Guidelines for case management of malaria in Ghana. Accra: Ministry of Health; 2020."},{"key":"6961_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12936-019-2848-1","volume":"18","author":"B Abuaku","year":"2019","unstructured":"Abuaku B, Duah-Quashie NO, Quaye L, Matrevi SA, Quashie N, Gyasi A, et al. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015\u20132017. Malar J. 2019;18:206.","journal-title":"Malar J"},{"key":"6961_CR14","volume-title":"Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003."},{"key":"6961_CR15","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"issue":"2","key":"6961_CR16","first-page":"55","volume":"42","author":"K Koram","year":"2008","unstructured":"Koram K, Quaye L, Abuaku B. Efficacy of Amodiaquine\/Artesunate combination therapy for uncomplicated malaria in children under five years in Ghana. Ghana Med J. 2008;42(2):55\u201360.","journal-title":"Ghana Med J"},{"key":"6961_CR17","unstructured":"Abuaku B, Quaye L, Quashie N, Quashie N, Koram K. Managing antimalarial drug resistance in Ghana: the importance of surveillance. In: Koram KA, Ahorlu CS, Wilson MD, Yeboah-Manu D, Bosompem KM, editors. Towards Effective Disease Control in Ghana: Research and Policy Implications. Vol. 1, Malaria. University of Ghana Reader Series. Accra: Sub-Saharan Publishers; 2014:7\u201318."},{"key":"6961_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/1475-2875-11-388","volume":"11","author":"B Abuaku","year":"2012","unstructured":"Abuaku B, Duah N, Quaye L, Quashie N, Koram K. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J. 2012;11:388.","journal-title":"Malar J"},{"issue":"1","key":"6961_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12936-015-1080-x","volume":"15","author":"B Abuaku","year":"2016","unstructured":"Abuaku B, Duah N, Quaye L, Quashie N, Malm K, Bart-Plange C, Koram K. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of uncomplicated malaria in two ecological zones in Ghana. Malar J. 2016;15(1):6.","journal-title":"Malar J"},{"key":"6961_CR20","unstructured":"World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Halth Organization. 29\u201331 May 2007, Amsterdam, The Netherlands. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43824\/9789241596305_eng.pdf?sequence=1&isAllowed=y. Accessed 7 Oct 2021."},{"key":"6961_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4269\/ajtmh.15-0826","volume":"97","author":"BK Abuaku","year":"2017","unstructured":"Abuaku BK, Mensah BA, Ofori MF, Myers-Hansen J, Derkyi-Kwarteng AN, Essilfie F, et al. Efficacy of artesunate\/amodiaquine in the treatment of uncomplicated malaria among children in Ghana. Am J Trop Med Hyg. 2017;97:690\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"6961_CR22","unstructured":"Global Malaria Programme. Artemisinin resistance and artemisinin-based combination therapy efficacy. Status report, August 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274362\/WHO-CDS-GMP-2018.18-eng.pdf?ua=1. Accessed 12 May 2021."},{"key":"6961_CR23","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.2147\/IDR.S167518","volume":"11","author":"OA Toure","year":"2018","unstructured":"Toure OA, Landry TNG, Assi SB, Kone AA, Gbessi EA, Ako BA, et al. Malaria parasite clearance from patients following artemsinin-based combination therapy in C\u00f4te d\u2019Ivoire. Infect Drug Resist. 2018;11:2031\u20138.","journal-title":"Infect Drug Resist"},{"key":"6961_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ijid.2020.03.082","volume":"95","author":"A Kone","year":"2020","unstructured":"Kone A, Sissoko S, Fofana B, Sangare CO, Dembele D, Haidara AS, et al. Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy. Int J Infect Dis. 2020;95:399\u2013405.","journal-title":"Int J Infect Dis"},{"key":"6961_CR25","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1038\/s41598-020-65553-5","volume":"10","author":"MA Diallo","year":"2020","unstructured":"Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Sci Rep. 2020;10:8907.","journal-title":"Sci Rep"},{"key":"6961_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.11604\/pamj.2020.35.68.20849","volume":"35","author":"I Zongo","year":"2020","unstructured":"Zongo I, Compaor\u00e9 YD, Niki\u00e9ma F, Zongo M, Barry N, Som\u00e9 FA, et al. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan Afr Med J. 2020;35:68.","journal-title":"Pan Afr Med J"},{"key":"6961_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12936-021-03890-0","volume":"20","author":"FO Maiga","year":"2021","unstructured":"Maiga FO, Wele M, Toure SM, Keita M, Tangara CO, Refeld RR, et al. Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis. Malar J. 2021;20:356.","journal-title":"Malar J"},{"key":"6961_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12936-021-03809-9","volume":"20","author":"MS Cherif","year":"2021","unstructured":"Cherif MS, Dahal P, Beavogui AH, Delamou A, Lama EK, Camara A, et al. Malaria epidemiology and anti-malarial drug efficacy in Guinea: a review of clinical and molecular studies. Malar J. 2021;20:272.","journal-title":"Malar J"},{"key":"6961_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4269\/ajtmh.21-0086","volume":"105","author":"A Kpemasse","year":"2021","unstructured":"Kpemasse A, Dagnon F, Saliou R, Maye SY, Affoukou CD, Zoulkaneri A, et al. Efficacy of artemether-lumefantrine for the treatment of Plasmodium falciparum Malaria in Bohicon and Kandi, Republic of Benin, 2018\u20132019. Am J Trop Med Hyg. 2021;105:670\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"6961_CR30","unstructured":"Federal Ministry of Health. Therapeutic efficacy study of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children. https:\/\/www.health.gov.ng\/doc\/2018-TES-FINAL-REPORT.pdf. Accessed 8 Oct 2021."},{"key":"6961_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Ringwald P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar J. 2021;20:320.","journal-title":"Malar J"},{"key":"6961_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","volume":"213","author":"A Yeka","year":"2016","unstructured":"Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, et al. Artesunate\/amodiaquine versus artemether\/lumefantrine for the treatment of uncomplicated malaria in uganda: a randomized trial. J Infect Dis. 2016;213:1134\u201342.","journal-title":"J Infect Dis"},{"key":"6961_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12936-020-03320-7","volume":"19","author":"P Hodoameda","year":"2020","unstructured":"Hodoameda P, Duah-Quashie NO, Hagan OC, Matrevi S, Abuaku B, Koram K, et al. Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana. Malar J. 2020;19:255.","journal-title":"Malar J"},{"key":"6961_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/1475-2875-12-377","volume":"12","author":"NO Duah","year":"2013","unstructured":"Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, et al. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar J. 2013;12:377.","journal-title":"Malar J"},{"key":"6961_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13071-018-2762-3","volume":"11","author":"T Adams","year":"2018","unstructured":"Adams T, Ennuson NAA, Quashie NB, Futagbi G, Matrevi S, Abuaku B, et al. Prevalence of Plasmodium falciparum delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubq1) genes in Ghanaian isolates. Parasit Vectors. 2018;11:175.","journal-title":"Parasit Vectors"},{"issue":"11","key":"6961_CR36","doi-asserted-by":"publisher","first-page":"e00802","DOI":"10.1128\/AAC.00802-19","volume":"63","author":"SA Matrevi","year":"2019","unstructured":"Matrevi SA, Opoku-Agyeman P, Quashie NB, Bruku S, Abuaku B, Koram KA, et al. Plasmodium falciparum Kelch Propeller Polymorphisms in Clinical Isolates from Ghana from 2007 to 2016. Antimicrob Agents Chemother. 2019;63(11):e00802-e819.","journal-title":"Antimicrob Agents Chemother"},{"key":"6961_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s13071-016-1692-1","volume":"9","author":"NO Duah","year":"2016","unstructured":"Duah NO, Matrevi SA, Quashie NB, Abuaku B, Koram KA. Genetic diversity of Plasmodium falciparum isolates from uncomplicated malaria cases in Ghana over a decade. Parasit Vectors. 2016;9:416.","journal-title":"Parasit Vectors"},{"key":"6961_CR38","unstructured":"National Center for Biotechnology. PubChem Compound Summary for CID 2165, Amodiaquine. https:\/\/pubchem.ncbi.nlm.nih.gov\/Amodiaquine. Accessed 15 Apr 2021."},{"key":"6961_CR39","unstructured":"National Center for Biotechnology. PubChem Compound Summary for CID 6437380, Lumefantrine. https:\/\/pubchem.ncbi.nlm.nih.gov\/Lumefantrine. Accessed 15 Apr 2021."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06961-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06961-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06961-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:09:14Z","timestamp":1639562954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06961-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6961"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06961-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were approved by the Institutional Review Board of the University of Ghana Noguchi Memorial Institute for Medical Research (UG-NMIMR), and followed the declaration of Helsinki. Children were enrolled into the studies after parents\/guardians had given their consent by signing\/thumb-printing a written informed consent form. Children aged 12-14\u00a0years also signed a written informed assent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1255"}}